Dihexa and Parkinson's: separating early science from TikTok hype

What did @intervenemd actually say?

The creator, who identifies as a physician, told viewers they have personally used Dihexa on patients and seen it "really help." They then connected that clinical anecdote to Michael J. Fox Foundation research, and made three specific mechanistic claims: that Dihexa helps brain cells "communicate better," protects existing cells, and helps "grow new cells in as little as 34 days." They also flagged oral bioavailability as a distinguishing feature. The framing throughout was optimistic, stopping just short of a cure claim, but the rhetorical direction was clear: Dihexa might let the brain "repair itself" from Parkinson's.

The video closes with a standard disclaimer that research is early, but that disclaimer does limited work after two minutes of specific mechanistic and clinical assertions. Viewers are left with the impression this is a promising intervention their doctor might offer them soon.

Does the science back this up?

The honest answer is: some of it, in animals, in controlled lab conditions, years ago. The Michael J. Fox Foundation connection is real but overstated in context. The "34 days" claim is specific enough to demand a citation, and none was given.

Dihexa (PNB-0408, also written N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by Joseph Harding and colleagues at Washington State University. Their 2013 paper in the Journal of Pharmacology and Experimental Therapeutics showed that Dihexa was roughly 10 million times more potent than BDNF in potentiating HGF/c-Met signaling, which has downstream effects on synaptogenesis in rodent models. That is a legitimately striking finding. McCoy et al. (2013) also demonstrated cognitive improvements in aged rats. These are real studies worth knowing about.

However, there are no completed human clinical trials for Dihexa in any condition as of early 2025. The Michael J. Fox Foundation has funded early-stage research involving HGF pathway modulation, but the creator's framing implies active human trials, which is not accurate. The jump from rodent synaptogenesis data to "it helps you grow new cells in as little as 34 days" in a human patient population is not supported by published evidence.

What did they get wrong (or right)?

Credit where it's due: the core neuroscience is accurate. Parkinson's does involve the progressive loss of dopaminergic neurons affecting movement. HGF/c-Met signaling is a real and studied neuroprotective pathway. Oral bioavailability is a genuine reported feature of Dihexa compared to most peptides, per Harding's original work. These points are not spin.

But several claims cross a line. Saying "I've used it on my patients and seen it really help" is anecdotal evidence presented as clinical validation. That is a problem regardless of how promising the compound looks on paper. Patient-reported improvements without controls, without standardized outcome measures, and without published results are not data. They're stories.

The "34 days" figure for new cell growth is specific and unverified. It appears to reference neurogenesis timelines cited in some nootropic community sources, not a peer-reviewed finding in humans or even primates. Presenting it as fact without a citation is misleading. And framing the Michael J. Fox Foundation's research interest as evidence that this peptide works conflates scientific curiosity with established efficacy.

What should you actually know?

Dihexa is a research compound. It is not FDA-approved for any indication. It is not available at licensed pharmacies as a finished drug product. Compounded versions exist and are being sold through telehealth channels, including, apparently, the creator's own platform. That commercial context matters when evaluating the enthusiasm.

The underlying biology is interesting. HGF signaling genuinely plays a role in neuronal survival, and finding a small molecule that potentiates it orally would be significant if proven in humans. But the gap between a promising rat study and a Parkinson's therapy is enormous, and that gap is filled with failed human trials in neurology every single year.

If you have Parkinson's or know someone who does, the current standard of care, including levodopa, MAO-B inhibitors, and deep brain stimulation, has decades of human evidence behind it. A peptide sold through a functional medicine clinic based on rodent data and physician anecdote is not a comparable option. Anyone offering Dihexa as a treatment for neurodegeneration should be asked for their IRB approval and published outcomes, not just their enthusiasm.